SGLT2抑制劑之心血管和腎臟結果試驗及嚴重副作用：統合分析

Cardiovascular and Renal Outcomes and Serious Side Effects of SGLT2 Inhibitors: A Meta-analysis

10.3966/168232812019062902001

蔡崇煌(Chung-Huang Tsai)；張加憲(Chia-Hsien Chang)；王俊堯(Jiun-Yao Wang)；曾立年(Li-Nien Tseng)

心血管結果試驗 ； 因心衰竭住院 ； 主要不良心血管事件 ； 腎臟疾病進展組合 ； CVOTs ； EndNote ； HHF ； MACE ； renal composite

台灣家庭醫學雜誌

29卷2期（2019 / 06 / 01）

57 - 67

繁體中文

背景：國內使用的3種口服降血糖藥之鈉－葡萄糖協同轉運蛋白2抑制劑（SGLT2i）的大型心血管結果試驗（CVOTs）皆已發表，但尚缺乏其分析比較，本研究目的為探討SGLT2i的CVOTs和腎臟結果試驗及較嚴重副作用，並做一統合分析。方法：以關鍵字“SGLT2 inhibitor＂OR＂SGLT2 inhibitors＂，AND＂meta-analysis＂OR ＂systematic review＂，搜尋2018年11月24日前之PubMed medline、Cochrane、Web of Science及CEPS中文思博網等資料庫。使用Review Manager 5.3軟體計算風險比（HRs）、95%信賴區間（CIs）及權重，並用MS-Excel及其VBA（Visual Basic for Applications）做森林圖（forest plot），若誤差線（error bar）未交叉到1.0無效線，表示達統計學上顯著的差異。結果：共找到3篇相關文獻做引用，整體而言，SGLT2i可顯著地降低因心衰竭住院（HHF）31%（HR 0.69, 0.61-0.79）和腎臟疾病進展組合（renal composite）45%（0.55, 0.48-0.64），且在3個研究中有相當一致的結果，其HRs皆相差不多。其餘除了心血管死亡（CVM）、非死亡腦中風及全因死亡率（ACM）外之變項亦皆有相當一致的結果。在主要不良心血管事件（MACE）雖只降低11%（0.89, 0.83-0.96），但有統計學上顯著差異。Canagliflozin在截肢（1.97, 1.41-2.75）、骨折（1.55, 1.21-1.97）及糖尿病酮酸中毒（DKA）（2.33, 0.76-7.17）皆有較高風險，且其前2項皆達統計學上顯著的差異，三種藥物之三者副作用之統合分析依序上昇26%（1.26, 1.06-1.51）、11%（1.11, 1.00-1.23）及120% （2.20, 1.25-3.87），且皆達統計學上顯著的差異。結論：SGLT2i可降低MACE、HHF和renal composite，除了CVM、非死亡腦中風及ACM外之變項皆有相當一致的結果。截肢、骨折及DKA皆以canagliflozin有較高風險。

Purpose: In spite of the publication of three large-scale cardiovascular outcome trials (CVOTs) of sodium-glucose cotransporters 2 inhibitors (SGLT2i), comparative analysis remains rare. The study accordingly aimed to compare the cardiovascular and renal outcomes and serious side effects of SGLT2i and to conduct a meta-analysis (M-A). Methods: We searched PubMed, Cochrane and Web of Science in EndNote X9 for trials published up to November 24, 2018, using the following keywords: ＂SGLT2 inhibitor＂ OR ＂SGLT2 inhibitors＂ AND ＂meta-analysis＂ OR ＂systematic review.＂ The study also searched CEPS with the same keywords in Chinese. Review Manager was used to calculate the hazard ratios (HRs) with 95% CI and weights, and forest plots drawn with MS-Excel with VBA. Significant difference was indicated if the error bars did not cross the no-effect line 1.0. Results: A total of three references were cited. Overall, SGLT2i was able to robustly reduce hospitalization for heart failure (HHF) by 31% (HR 0.69, 95% CI 0.61-0.79) and renal composite by 45% (0.55, 0.48-0.64), and the results appeared to be fairly consistent in three of the four references. Except cardiovascular mortality (CVM), non-fatal stroke, and all-cause mortality (ACM), the results concerning other variables stayed consistent. SGLT2i moderately reduce major adverse cardiovascular events (MACE) by 11.0% with significant difference (0.89, 0.83- 0.96) noted. Compared to the other two agents, Canagliflozin incurred a higher risk in amputation (1.97, 1.41-2.75), fracture (1.55, 1.21-1.97) and diabetic ketoacidosis (DKA) (2.33, 0.76-7.17), while the M-A found all the three side effects reaching significant differences with 26% (1.26, 1.06-1.51), 11% (1.11, 1.00-1.23), and 120% (2.20, 1.25-3.87) respectively. Conclusion: SGLT2i helps reduce MACE, HHF and the progression of renal disease. Except CVM, non-fatal stroke, and ACM, variables are marked with fairly consistent results. Canagliflozin poses greater risks on amputation, fracture and DKA than the other two agents.

1. Cavender, MA,Steg, PG,Smith, SC, Jr(2015).Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry.Circulation,132,923-931.
2. Center for Drug Evaluation and Research. Guidance for Industry Diabetes Mellitus: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed November 24, 2018.
3. Cherney, DZ,Perkins, BA,Soleymanlou, N(2014).Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.Circulation,129,587-597.
4. Chiang, CE,Lin, SY,Lin, TH(2018).2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.JCMA,81,189-222.
5. Davies, MJ,D'Alessio, DA,Fradkin, J(2018).Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetes Care,41,2669-2701.
6. DeFronzo, RA,Norton, L,Abdul-Ghani, M(2017).Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.Nat Rev Nephrol,13,11-26.
7. Devineni, D,Polidori, D(2015).Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor.Clin Pharmacokinet,54,1027-1041.
8. Garg, SK,Peters, AL,Buse, JB,Danne, T(2018).Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol.Diabetes Technol Ther,20,571-575.
9. Gerstein, HC,Miller, ME,Byington, RP(2008).Effects of intensive glucose lowering in type 2 diabetes.N Engl J Med,358,2545-2559.
10. Goldenberg, RM,Berard, LD,Cheng, AYY(2016).SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis.Clin Ther,38,2654-2664 e1.
11. Heerspink, HJ,Perkins, BA,Fitchett, DH,Husain, M,Cherney, DZ(2016).Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications.Circulation,134,752-772.
12. Home, PD,Pocock, SJ,Beck-Nielsen, H(2009).Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.Lancet,373,2125-2135.
13. Huang, CJ,Wang, WT,Sung, SH(2018).Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: evidence from meta-regression analysis of randomized controlled trials.Diabetes Obes Metab,20,2131-2139.
14. Neal, B,Perkovic, V,Mahaffey, KW(2017).Canagliflozin and cardiovascular and renal events in type 2 diabetes.N Engl J Med,377,644-657.
15. Nissen, SE,Wolski, K(2007).Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med,356,2457-2471.
16. Nissen, SE,Wolski, K(2010).Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.Arch Intern Med,170,1191-1201.
17. Nyirjesy, P,Sobel, JD,Fung, A(2014).Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.Curr Med Res Opin,30,1109-1119.
18. Patel, A,MacMahon, S,Chalmers, J(2008).Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med,358,2560-2572.
19. Rawshani, A,Rawshani, A,Franzen, S(2017).Mortality and cardiovascular disease in type 1 and type 2 diabetes.N Engl J Med,376,1407-1418.
20. Rosenstock, J,Perkovic, V,Johansen, OE(2019).Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA Randomized Clinical Trial.JAMA,32,69-79.
21. Ryan, PB,Buse, JB,Schuemie, MJ(2018).Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D).Diabetes Obes Metab,20,2585-2597.
22. Scheen, AJ(2014).Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor.Clin Pharmacokinet,53,213-225.
23. Schnell, O,Ryden, L,Standl, E,Ceriello, A(2016).Current perspectives on cardiovascular outcome trials in diabetes.Cardiovasc Diabetol,15,139.
24. Watts, NB,Bilezikian, JP,Usiskin, K(2016).Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus.J Clin Endocrinol Metab,101,157-166.
25. Wiviott, SD,Raz, I,Bonaca, MP(2019).Dapagliflozin and cardiovascular outcomes in type 2 diabetes.N Engl J Med,380,347-357.
26. Zelniker, TA,Braunwald, E(2018).Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC State-of-the-Art Review.J Am Coll Cardiol,72,1845-1855.
27. Zelniker, TA,Wiviott, SD,Raz, I(2019).SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.Lancet,393,31-39.
28. Zinman, B,Inzucchi, SE,Lachin, JM(2017).Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk.Stroke,48,1218-1225.
29. Zinman, B,Wanner, C,Lachin, JM(2015).Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med,373,2117-2128.

1. 顏啟華,蔡崇煌,曾立年,張惠雯,江韶岳(2020)。降血糖藥物之心血管結果試驗：系統回顧及統合分析。台灣家庭醫學雜誌，30(3)，153-168。